drugset / Trial / NCT03628612

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612 ↗

Phase 2 Enrolling by invitation 500 enrolled Autolus Limited
NaSingle-groupOpen-labelOther

Summary

Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

Timeline

Start
2018-08-02
Primary completion
2043-07
Completion
2043-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AUTO CAR T cell therapy Cell therapy — —